{ "story_id": "90d20cd5eb4839193a57cf87bbdb49e5", "desk": "drm3", "revision": 1, "published_at": "2026-09-01T18:40:09.000Z", "content_hash": "84c8f823f8e91613bbf0e4cf07cd6ff8decace3a12f118ec8d02d8d54321f16d", "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs", "basis": { "headline": "Bayer to Focus on 10 Blockbuster Crops for 500 Million Euro Profit", "dek": "Bayer is restructuring its portfolio to focus on 10 agricultural products expected to generate significant revenue.", "prose": "Bayer AG announced a strategic restructuring of its agricultural portfolio to focus on 10 key blockbuster products, aiming to generate 500 million euros in profit from each. [^1]\n\nBayer is introducing Preceon, a low-height corn system already commercialized in Mexico, Italy, Spain, and the United States, with plans to expand to 26 million acres by 2035. [^2]\n\nIn Brazil, Bayer plans to launch Intacta 5+ during the 2027-2028 agricultural cycle, featuring five herbicide tolerances and new insect protection attributes. [^3]\n\nThe restructuring involves cutting investments in lower-performing product lines, with the company expecting these measures to contribute an additional 1,000 million euros to its EBITDA before extraordinary items by the end of the decade. [^4]\n\nA research paper titled 'Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium' reports on the short-term impact of combined heart failure therapies on these three clinical parameters. [^5]\n\nThe article's data availability statement says all trial funders are committed to sharing access to patient-level data and supporting clinical documents from eligible studies, subject to each funder's criteria and processes. [^6]\n\nThe trial funders named in the data availability statement are AstraZeneca, Bayer, Novartis, and Pfizer, each with its own data-sharing criteria and processes. [^7]\n\nThe paper's reference list includes the American Heart Association's 2026 Heart Disease and Stroke Statistics and numerous studies on heart failure pharmacotherapy, such as the CHAMP-HF registry and the STRONG-HF trial. [^8]", "cited": "[{\"statement\":\"Bayer AG announced a strategic restructuring of its agricultural portfolio to focus on 10 key blockbuster products, aiming to generate 500 million euros in profit from each.\",\"source\":\"Expansión News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:40:09.000Z\",\"publisher_count\":1,\"sources\":[\"Expansión News\"]},{\"statement\":\"Bayer is introducing Preceon, a low-height corn system already commercialized in Mexico, Italy, Spain, and the United States, with plans to expand to 26 million acres by 2035.\",\"source\":\"Expansión News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:40:09.000Z\",\"publisher_count\":1,\"sources\":[\"Expansión News\"]},{\"statement\":\"In Brazil, Bayer plans to launch Intacta 5+ during the 2027-2028 agricultural cycle, featuring five herbicide tolerances and new insect protection attributes.\",\"source\":\"Expansión News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:40:09.000Z\",\"publisher_count\":1,\"sources\":[\"Expansión News\"]},{\"statement\":\"The restructuring involves cutting investments in lower-performing product lines, with the company expecting these measures to contribute an additional 1,000 million euros to its EBITDA before extraordinary items by the end of the decade.\",\"source\":\"Expansión News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T18:40:09.000Z\",\"publisher_count\":1,\"sources\":[\"Expansión News\"]},{\"statement\":\"A research paper titled 'Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium' reports on the short-term impact of combined heart failure therapies on these three clinical parameters.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T16:20:59.636Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"The article's data availability statement says all trial funders are committed to sharing access to patient-level data and supporting clinical documents from eligible studies, subject to each funder's criteria and processes.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T16:20:59.636Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"The trial funders named in the data availability statement are AstraZeneca, Bayer, Novartis, and Pfizer, each with its own data-sharing criteria and processes.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T16:20:59.636Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"The paper's reference list includes the American Heart Association's 2026 Heart Disease and Stroke Statistics and numerous studies on heart failure pharmacotherapy, such as the CHAMP-HF registry and the STRONG-HF trial.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T16:20:59.636Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]}]", "kind": "news" }, "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature", "receipt": null, "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record", "generation_chain": { "wire": { "stream": "fountain_news", "story_id": "6133fec9aa67b948ee22425dbbf3d0fc", "thread_id": "9c7db02a7fb7181fa4a6b316c273afc2", "thread_label": "Bayer", "novelty": "UPDATE", "content_hash": "06883b722110ddbb2e4df9a7e115d449d14437a369afe15313ecb6c555bcbd1b", "last_published_at": "2026-09-01T18:40:09.000Z", "read_receipt": { "slice_hash": "687c21cfee1c67e018c8b08b28ee16bdbdf0694c6eb4d36eccec996f24e4e1cc", "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMTg6Mjc6MzYuMDAwMDAwWiIsImlkIjoiMTYzMzQ3YTc2ZmVlNTI5NzE4YzVkMjAxMThiZDE3MmQiLCJ2IjoiMSJ9", "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMTk6MTA6MzkuMDAwMDAwWiIsImlkIjoiMDIyYzEwN2E3ZWUwNzgxMWY1MjQ4MDc2ZDZlYmIzZjAiLCJ2IjoiMSJ9", "view": "v_fountain_news", "view_version": "1", "row_count": 100, "window_days": 3, "bytes_scanned": 12017721, "credits": 8, "price_per_100_rows": 8, "sig": "B6kAds9LFD0ZC8IKkGpLD6SIMTS2p3jgnKgIb5wYy9CzFD76zpdo0kAnX_OOdpfXlKC3_Vjxvhdjn3dCPBJPDA", "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE", "signer_path": "lakehouse/data-extract/v1", "alg": "Ed25519", "signed": true } }, "written_at": "2026-09-02T22:11:12.584Z" }, "cited_facts": [ { "statement": "Bayer AG announced a strategic restructuring of its agricultural portfolio to focus on 10 key blockbuster products, aiming to generate 500 million euros in profit from each.", "source": "Expansión News", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T18:40:09.000Z", "publisher_count": 1, "sources": [ "Expansión News" ] }, { "statement": "Bayer is introducing Preceon, a low-height corn system already commercialized in Mexico, Italy, Spain, and the United States, with plans to expand to 26 million acres by 2035.", "source": "Expansión News", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T18:40:09.000Z", "publisher_count": 1, "sources": [ "Expansión News" ] }, { "statement": "In Brazil, Bayer plans to launch Intacta 5+ during the 2027-2028 agricultural cycle, featuring five herbicide tolerances and new insect protection attributes.", "source": "Expansión News", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T18:40:09.000Z", "publisher_count": 1, "sources": [ "Expansión News" ] }, { "statement": "The restructuring involves cutting investments in lower-performing product lines, with the company expecting these measures to contribute an additional 1,000 million euros to its EBITDA before extraordinary items by the end of the decade.", "source": "Expansión News", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T18:40:09.000Z", "publisher_count": 1, "sources": [ "Expansión News" ] }, { "statement": "A research paper titled 'Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium' reports on the short-term impact of combined heart failure therapies on these three clinical parameters.", "source": "Nature", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T16:20:59.636Z", "publisher_count": 1, "sources": [ "Nature" ] }, { "statement": "The article's data availability statement says all trial funders are committed to sharing access to patient-level data and supporting clinical documents from eligible studies, subject to each funder's criteria and processes.", "source": "Nature", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T16:20:59.636Z", "publisher_count": 1, "sources": [ "Nature" ] }, { "statement": "The trial funders named in the data availability statement are AstraZeneca, Bayer, Novartis, and Pfizer, each with its own data-sharing criteria and processes.", "source": "Nature", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T16:20:59.636Z", "publisher_count": 1, "sources": [ "Nature" ] }, { "statement": "The paper's reference list includes the American Heart Association's 2026 Heart Disease and Stroke Statistics and numerous studies on heart failure pharmacotherapy, such as the CHAMP-HF registry and the STRONG-HF trial.", "source": "Nature", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T16:20:59.636Z", "publisher_count": 1, "sources": [ "Nature" ] } ], "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true." }